进行性肾细胞癌症治疗的全球市场:现状分析与预测(2022年～2028年)

全球进行性肾细胞癌症治疗的市场规模，在预测期间内预计以约5％的年复合成长率成长。标靶治疗药迅速的核准和与传统治疗药比较的高有效性，推动市场成长。还有老年人口增加，肾臟癌症的盛行率上升，医疗支出增加，製药大幅投资剧增，也促进市场成长。

本报告提供全球进行性肾细胞癌症治疗市场的相关调查，市场洞察，市场趋势，竞争模式，企业概要等全面性资讯。

目录

第1章 市场简介

• 市场定义
• 主要的目标
• 相关利益者
• 限制

第2章 调查手法或假设

• 进行性肾细胞癌症治疗市场调查流程
• 进行性肾细胞癌症治疗市场调查手法
• 受访者简介

第3章 市场摘要

第4章 摘要整理

第5章 COVID-19对进行性肾细胞癌症治疗市场的影响

第6章 进行性肾细胞癌症治疗市场收益(10亿美元)(2020年～2028年)

第7章 市场洞察:各治疗

• 化疗
• 生技药品
• 其他

第8章 市场洞察:各给药途径

• 口服
• 非口服
• 其他

第9章 市场洞察:各最终用途

• 医院药局
• 零售药局
• 线上药局

第10章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他的北美
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他的欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他的亚太地区
• 全球其他地区

第11章 进行性肾细胞癌症治疗的市场动态

• 推动市场要素
• 市场课题
• 影响分析

第12章 进行性肾细胞癌症治疗的市场机会

第13章 进行性肾细胞癌症治疗的市场趋势

第14章 需求面和供给方面的分析

• 需求面分析
• 供给面

第15章 价值链分析

第16章 竞争模式

• 竞争情形
  • 波特的五力分析

第17章 企业概要

• Bristol-Myers Squibb Company
• Novartis AG
• Pfizer Inc.
• Genentech, Inc
• GSK plc.
• Bayer AG
• Eisai Co., Ltd
• Exelixis, Inc.
• Merck KGaA
• NiKang Therapeutics, Inc.

第18章 免责声明

Renal cell carcinoma (RCC) represents about 0%-95% of kidney cancers. And, approximately, 30% of RCC cases are diagnosed at the advanced or metastatic stage. The mainstay treatment of advanced renal cell carcinoma include tyrosine kinase inhibitors, vascular endothelial growth factor inhibitors, chemotherapy, and other. However, with the increase in the understanding of cancer biology, researchers have developed novel targeted therapies such as monoclonal antibodies, immune checkpoint inhibitors, immune modulators, and others. For instance, in August 2021, U.S. FDA granted approval to the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for first-line treatment of adult patients with advanced renal cell carcinoma. Thus, rapid approval of targeted therapies and their high efficacy in comparison to conventional therapies is driving the growth of the market.

The Advanced Renal Cell Carcinoma Treatment Market is expected to grow at a steady rate of around 5% owing to technological advancements and an increase in investment by pharmaceutical giants. The key players are rapidly launching novel products, which are also having a positive impact on market growth. For instance, in November 2021, NiKang Therapeutics Inc. entered into clinical trial collaboration with Pfizer Inc. The collaboration aims to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with palbociclib, a CDK4/6 inhibitor, and sasanlimab, a subcutaneously administered PD-1 inhibitor for the treatment of advanced clear cell renal cell carcinoma (ccRCC).

Based on treatment, the market is segmented into chemotherapy, biologics, and others. The biologics segment is expected to grow with a high CAGR during the forecast period which is attributed to its targeted nature, high cost, and high efficiency. Moreover, key players are launching products in the market which is also expected to have a positive impact on the growth of the market. For instance, in January 2021, U.S. FDA approved the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) as first-line treatment for patients with advanced renal cell carcinoma. The approval was on the basis of CHECKMATE-9ER trial, which demonstrated significant improvement in progression-free survival and overall survival rates.

On the basis of the route of administration, the market is categorized into oral, parenteral, and other. The oral route held a significant share of the market in 2020. It is the most common and acceptable route of administration as it is cheap, simple, and safest. Moreover, it is highly economical as does not involve the patient in extra cost. Thus, these factors are driving segmental growth.

On the basis of end-use, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy held a significant share in the market in 2020. The rising prescription of medications at hospitals due to more frequent diagnoses at these institutions is a major factor driving the segment growth. Moreover, the increasing preference of patients to avail treatment in hospitals and the easy availability of medication in hospital pharmacies. Also, the tendency of consumers to visit hospital pharmacies for safe and authorized drugs is also driving the growth of this segment.

For a better understanding of the market adoption of the advanced renal cell carcinoma treatment, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. Several factors, such as the rise in the geriatric population, the rise in the prevalence of kidney cancer, rising healthcare expenditures, and a surge in investments by pharmaceutical giants are driving the regional growth. For instance, in October 2022, Hutchmed initiated a Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma in China. The first patient in China received the first dose on October 27, 2022. Moreover, in March 2020, Japanese Ministry of Health, Labor and Welfare granted approval to cabometyx (cabozantinib) in Japan, for the treatment for patients with curatively unresectable or metastatic renal cell carcinoma.

Some of the major players operating in the market include: Bristol-Myers Squibb Company; Novartis AG; Pfizer Inc.; Genentech, Inc; GSK plc.; Bayer AG; Eisai Co., Ltd; Exelixis, Inc.; Merck KGaA; NiKang Therapeutics, Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Advanced Renal Cell Carcinoma Treatment Market
• 2.2. Research Methodology of the Advanced Renal Cell Carcinoma Treatment Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET

6 ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TREATMENT

• 7.1. Chemotherapy
• 7.2. Biologics
• 7.3. Others

8 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

• 8.1. Oral
• 8.2. Parenteral
• 8.3. Other

9 MARKET INSIGHTS BY END-USE

• 9.1. Hospital Pharmacy
• 9.2. Retail Pharmacy
• 9.3. Online Pharmacy

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET OPPORTUNITIES

13 ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. Bristol-Myers Squibb Company
• 17.2. Novartis AG
• 17.3. Pfizer Inc.
• 17.4. Genentech, Inc
• 17.5. GSK plc.
• 17.6. Bayer AG
• 17.7. Eisai Co., Ltd
• 17.8. Exelixis, Inc.
• 17.9. Merck KGaA
• 17.10. NiKang Therapeutics, Inc.

18 DISCLAIMER